Insights
Search Results
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
1.09.26
Wilson Sonsini Advises Link Cell Therapies on Strategic Collaboration with Johnson & Johnson
On January 9, 2026, Link Cell Therapies, an oncology cell therapy company, announced a strategic collaboration with Johnson & Johnson to develop novel logic-gated LINK CAR T therapies. The collaboration follows the recently announced Series A financing in Link that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc., which included participation of additional strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the matter.
Client Highlights
12.16.25
Wilson Sonsini Advises Link Cell Therapies on Series A Financing
On December 15, 2025, Link Cell Therapies, an oncology cell therapy company, announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors. Wilson Sonsini Goodrich & Rosati advised Link Cell Therapies on the transaction.
Client Highlights
10.28.25
Wilson Sonsini Advises Empirico on License Agreement with GSK
On October 28, 2025, GSK and Empirico, a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, announced that they have entered into a worldwide exclusive license agreement for EMP-012, a highly selective first- and potentially best-in-class siRNA, a type of oligonucleotide. EMP-012 addresses a novel therapeutic target and is currently in a Phase 1 trial for the treatment of chronic obstructive pulmonary disease (COPD), with the potential for expansion into other inflammatory respiratory diseases. Wilson Sonsini Goodrich & Rosati advised Empirico on the transaction.
Client Highlights
7.11.24
Wilson Sonsini Advises Fluent BioSciences on Acquisition by Illumina
On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.
Client Highlights
2.06.24
Wilson Sonsini Advises Halia Therapeutics on $30 Million Series C Financing
On January 31, 2024, Utah-based Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, announced the completion of a $30 million Series C financing. The financing was led by Todd Pedersen, with continued participation from existing investors. Wilson Sonsini Goodrich & Rosati represented Halia Therapeutics in the transaction.
Client Highlights
10.12.23
Wilson Sonsini Advises BioMap on Strategic Collaboration with Sanofi
On October 10, 2023, BioMap, a disruptive life science AI company responsible for building the first and largest protein-centric large language model platform xTrimo, announced a strategic collaboration with Sanofi, a global healthcare and pharmaceutical company, to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. Wilson Sonsini Goodrich & Rosati advised BioMap on the transaction.
Client Highlights
8.29.23
Wilson Sonsini Represents Thorne HealthTech in Sale to L Catterton
On August 28, 2023, Thorne HealthTech, Inc., a leader in delivering innovative solutions for a personalized approach to health and wellness, announced that it has entered into a definitive agreement under which L Catterton, a leading global consumer-focused investment firm, will commence a tender offer to acquire all outstanding shares of common stock of Thorne for $10.20 per share in cash. The transaction value of approximately $680 million represents a 94 percent premium to the unaffected closing share price on July 20, 2023, and a 113 percent premium to the 30-day volume weighted average price as of the unaffected date of July 20, 2023. Thorne's independent Special Committee and board of directors have each unanimously approved the agreement and recommend that Thorne’s stockholders tender their shares into the tender offer. Wilson Sonsini Goodrich & Rosati represented Thorne and the Special Committee of the board of directors in the transaction.
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes:
The transaction is expected to be completed in the fourth quarter of 2023, subject to customary closing conditions. Subject to the terms and conditions of the agreement, following the completion of the tender offer, L Catterton will acquire any shares of Thorne that are not tendered in the tender offer through a second-step merger for $10.20 per share in cash. Upon completion of the transaction, Thorne will become a privately held company and its shares of common stock will no longer be listed on any public market.
The Wilson Sonsini team that represented Thorne and the Special Committee of the board of directors includes:
Alerts
4.12.23
FDA Issues Draft Guidance Related to Marketing Submissions for AI/ML-Enabled DSFs, and Final Guidance Describing the FDA's Adoption of Section 524B "Ensuring Cybersecurity of Devices"
The U.S. Food and Drug Administration (FDA) is continuing its effort to provide industries with updated guidance for digital health technologies.
Alerts
3.31.23
FDA Issues Framework for Digital Health Technologies in Drug and Biological Product Development
This month, the U.S. Food and Drug Administration (FDA) released its Framework for the use of digital health technologies (DHTs) in drug and biological product development. This Framework is part of the FDA’s ongoing effort to support the increased use of DHTs for new drug applications, biologics license applications, supplements to those applications, and drug safety monitoring. DHTs include technologies such as wearable, implantable, ingestible, and environmental sensors, and software applications on mobile phones, among others. Advances in sensor technology, general-purpose computing platforms, and methods for data capture, transmission, and storage have revolutionized the ability to remotely obtain and analyze clinically relevant information from individuals. DHTs used for remote data acquisition are playing a growing role in healthcare and offer important opportunities in clinical research. DHTs can support traditional site-based clinical trials and enable the conduct of decentralized clinical trials, which are clinical investigations where some or all trial-related activities occur at locations other than traditional clinical trial sites.
Alerts
12.21.22
FDA’s Draft Guidance for Laser-Assisted In Situ Keratomileusis (LASIK) Lasers: Patient Labeling Recommendations
The U.S. Food and Drug Administration (FDA) is considering comments to their risk-focused draft guidance, “Laser-Assisted In Situ Keratomileusis (LASIK) Lasers-Patient Labeling Recommendations.” Although LASIK is one of the most commonly performed elective procedures in the world, responses to the draft guidance have been mixed.